Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Contineum Therapeutics (CTNM) EBT Margin (2023)

Historic EBT Margin for Contineum Therapeutics (CTNM) over the last 1 years, with Q2 2023 value amounting to 84.6%.

  • Contineum Therapeutics' EBT Margin changed N/A to 84.6% in Q2 2023 from the same period last year, while for Mar 2024 it was 39.17%, marking a year-over-year change of. This contributed to the annual value of 46.34% for FY2023, which is N/A changed from last year.
  • Per Contineum Therapeutics' latest filing, its EBT Margin stood at 84.6% for Q2 2023.
  • Contineum Therapeutics' 5-year EBT Margin high stood at 5243.48% for Q1 2023, and its period low was 84.6% during Q2 2023.